@entity39 and @entity631 with XXXX , Fifteen Years after Initial Diagnosis of @entity8 .

@entity1 @entity8 @entity39 @entity1252 @entity1988 @entity810 @entity631
Renal involvement in @entity1252 ( @entity1252 ) is usually immune complex mediated and may have multiple different presentations. Pauci-immune @entity39 and crescentic @entity631 (NCGN) refers to extensive @entity8 with few or no immune deposits that may result in rapid decline in renal function. We report a case of a 79-year-old Hispanic male with a history of secondary @entity8 (diagnosed by renal biopsy 15 years previously) who was admitted with @entity810 and active urinary sediment. P-ANCA titers and anti-myeloperoxidase antibodies were positive. The renal biopsy was diagnostic for NCGN superimposed on a secondary @entity8 . A previous diagnosis of @entity1252 based on American College of Rheumatology criteria was discovered via Veteran's Administration records review after the completion of treatment for pauci-immune NCGN. ANCAs are detected in 20-31% of @entity1 with @entity1252 . There may be an association between @entity1252 and ANCA seropositivity. In @entity1 with @entity1988 and biopsy findings of @entity39 and crescentic @entity631 , without significant immune complex deposition, ANCA testing should be performed. In @entity1 with secondary @entity8 @entity1252 should be excluded.
